ENDO2026

Endo is a specialty pharmaceutical company focused on developing and commercializing high-value branded and generic medicines. The company's branded portfolio is anchored by XIAFLEX, a biologic treatment for Dupuytren's contracture and Peyronie's disease, alongside other key products in urology and endocrinology such as AVEED and SUPPRELIN LA. Following a financial restructuring and emergence from bankruptcy in 2024, the company emerged as Endo, Inc. and subsequently merged with Mallinckrodt plc in 2025 to create a diversified therapeutics leader. Endo maintains a significant presence in the sterile injectables and generic pharmaceutical markets through its operating companies like Par Pharmaceutical.